Nemeroff is BACK, baybee! D. F. S.

(by drugmonkey) May 22 2012

Oh yes. Via pharmalot and Science Insider:

RePORTER tells us that the NIMH has funded:
1R01MH094759-01A1 "1 OF 2 - PROSPECTIVE DETERMINATION OF PSYCHOBIOLOGICAL RISK FACTORS FOR PTSD"
from 17 May 2012 to April of 2017. With Charles Nemeroff as the Principal Investigator.
To the tune of $401,675 total costs for FY 2012. His institution seems to come in at 53% overhead which would make it $263K in direct. Hmm. Maybe that IDC rate is outdated because why would you bother with a traditional budget just to request another $13K?

if you are wondering, as I was, "2 of 2" appears to be this project. This junior partner in the deal gets only $290K in total costs.

YHN on:
Nemeroff's third strike
Inselgate
Inselgate linkage

Nothing to say, really. It was a COI case where nobody really laid gloves on the guy for fraud. All he's really guilty of is underreporting his earnings from Big (and small) Pharma interests to his prior employer Emory U. That should have triggered a stink with his NIH awards but again the rules are about managing conflict...nothing to prove that he actually defrauded the NIH with faked research to benefit his corporate paymasters. Nothing like that ever confirmed. Plus a failure to disclose his conflicts on some review articles or whatnot. Again, if he had disclosed properly it is very likely nothing would have been done differently.

Still, the whole thing smells and I'm sad that it happened in fields which vaguely intersect with my interests. I'm sadder still that the NIH fails to recognize the effect it has on all the scientists who are busting their behinds to secure a grant and do good work that isn't tainted by conflict and extra-job income to the tune of hundreds of K per year in "consulting" gigs.

Dude. Fuck. Sigh.

Share

6 responses so far

NIH pilots special scrutiny of PIs with $1.5 M in total costs.

(by drugmonkey) May 18 2012

Thoughts on NOT-OD-12-110:

The threshold of $1.5 million total costs. How's that break down? Well if you are in a consensus ~50% overhead state university, let's see...Thats FOUR full-modular awards. But let's be clear, odds are you got cut by at least a module per award so that's only $900K direct..you get to be in a University with about 70% overhead and you are still clear. What bout the much-rumored 100% overhead small institutions? well, you get three R01s before you go under strict scrutiny.

I do wonder if this will satisfy all the "kill the rich" voices? Will they see this as the NIH taking them seriously or as a meaningless sop?

Next question, this is just identifying special Council level review...No guarantee that any grant will ever be blocked because the PI has too much $$. No guarantee that negotiations wouldn't be made either. "Say, PI Jones, would you please put some more junior colleague on as titular head to one of your other awards so we can give you this one"?

new MultiPI awards won't trigger the scrutiny unless all PIs trigger the threshold. Hello courtesy "multi"PIship!!!

It may possibly change some people's strategy so that they work harder to distribute effort around to other people's awards in small percentages. Like junior PI is going to screw BigCheeze over on the agreed upon part of the direct costs? No worries there.

How are study sections going to respond to this. Will they take this as the NIH saying "This is our threshold for being worried about too much money. Now shut up about this for anything below this amount."? Or will they take this as encouragement to think about lab size even more when they are reviewing the grant in front of them?

Share

24 responses so far

The NIH options for dealing with the budget stagnation are missing one...

(by drugmonkey) May 18 2012

The AAAS has a summary up which deals with NIH's head of the Office of Extramural Research Sally Rockey's comments on the FY13 budget for the NIH.

Sally J. Rockey, deputy director for extramural research at NIH, said that some changes in grants management already have been proposed as part of the president’s budget submission for the 2013 fiscal year.

and those solutions will be familiar to those following along at the RockTalk blog. It boils down to "kill the rich!!!". If you already have it, or have too much of it, they are gunning for you.

These include an across-the-board funding cut of 1% for continuing grants; negotiating the budgets for new competitive grants to avoid growth in the average size of award; eliminating increases for inflation in multi-year grants; giving additional scrutiny to researchers who already receive in excess of $1.5 million a year; and continuing to fund early-stage investigators at the same rate as established investigators for new grant applications.

The alternative posed by Rockey is "Darwinian".

“Many people thought we should keep the current system,” Rockey said. “Just keep the Darwinian approach. Don’t try to go in there and socially engineer anything.” Others weighed in on the merits of the various options for change, including some approaches beyond those discussed by Rockey. These could include limiting payment for indirect costs associated with grants, limiting large project grants, and providing more support to small labs and individuals by limiting grants to large labs.

Well it sure looks like this depiction to me.
Just about the only person who is not under potential attack under this scenario is the small town grocer. Otherwise known as Noonan. I have been reluctant*, I will admit, to even think very much about something that has been raised (identified?) by PhysioProf on numerous blog posts. It boils down to the suggestion that it is the Small Town Grocer scientists that are precisely who the NIH should be dropping from the system. Actually, PP tends to phrase this as a suspicion that this is just what the NIH is up to, rather than a suggestion that they should do so.

Since he's been making this comment I've gradually noticed that this option is never raised. Rockey maybe touched on it a teensy bit in the AAAS piece.

Institutions also could help manage the demand for grant money by reducing the number of applications submitted by their faculty, Rockey said. And NIH can examine its research priorities, seeking to reduce support for less innovative ideas and eliminating some of the duplication of effort.

Oh yeah. You do it for us, University of State. Right. Like that is in their interest. Sorry but we're in tragedy of the commons territory Dr. Rockey and you are going to have to do this yourself if you want it to happen. Take a hard run at the smaller, lesser and slower producing laboratories. Stop saving them with bridge funding, stop taking pity on your "long term funded investigators" and the like.

It is indubitably the case that we have too many investigators seeking too few grant dollars. All of the main solutions on the table are going to squeeze the most productive, best funded laboratories (not to mention the noobs who finally managed to land their first grant to find a cut that oblates a warm body). Just so that more awards can be made. To, presumably, the small timers.

And those more productive labs are going to fight back as best they can. Submit even MORE grant to make up for the cut funds. Work deals with their friends and junior colleagues to be collaborating investigators so to hide the amount of direct funds going into the laboratory. Pursue training grants, beg for supplements....whatever it takes. They are not going to go "hum, well, I'm just going to be happy with less".

And, sad but true, these are likely going to be the people on study section stepping down hard on, guess who? Investigators who are not like them.

You want Darwinian, Deputy Director Rockey?

If a better-funded, more-active reviewer is really thinking, s/he is best off bashing the crap out of one-trick-pony PI's grants. Why? Because you might just put them out of the game permanently! If you can do that, you've reduced the competition in a real way. Conversely if you stamp on a reasonably well funded and reasonably active PI, you haven't put them out of business at all. Just ensured they will put in yet more grants.

Look, I'm still not sure I know the best path. I love the democratic nature of the ideal of the NIH pure Investigator Initiated system. Anyone with a good idea should be able to get funding.

But I also believe that little gets done on one full modular, cut to $200/yr, maybe reduced to 4 yr grant anymore**. Research programs may not be efficient after 5 grants but they sure as heck aren't in the sweet spot with one either.

And I know for damn sure the insecurity and grant churning of the past 5-8 years has been hugely detrimental to the conduct of science.

Sadly, I don't see that any of the proposals of the NIH do anything to decrease churning.

UPDATE: see NOT-OD-12-110, just published today:

This Notice announces NIH’s intent to pilot procedures for investigator-initiated grants and cooperative agreements in consideration of managing resources during austere times. During May 2012 NIH Institute and Center (IC) Advisory Council meetings, Councils will discuss and pilot-test procedures for the additional review of grant and cooperative agreement applications from Program Director(s)/Principal Investigator(s) [PD(s)/PI(s)] who already receive in excess of $1.5 million per year in total costs to determine if additional funds should be provided to already well-supported investigators. The feedback from this pilot will help NIH further refine policies for managing limited grant resources.

__
The cartoon, btw, is stolen with apologies from Dent. I, uh, altered it.

*anyone who thinks their relative position in the NIH world is predictable or static needs their head examined. I could be calling for an option that will end my lab's viability here.

**Read this. It is short.

Share

21 responses so far

Mommy Warz: Spot the Illogic at, you guessed it, HuffPo

(by drugmonkey) May 17 2012

A recent HuffPo piece on that rather flagrant bit of cover trolling from TIME magazine irritates me.
Continue Reading »

Share

20 responses so far

Protected Pockets of Time

(by drugmonkey) May 16 2012

In yesterday's discussion, I finally got a partial glimpse of the issue when NatC observed:

Discussions about how to manage and plan protected pockets of time OUTSIDE work to do whatever - walk the bulldog, play music, train for a triathlon, watch baseball, play with your kids or nieces/nephews ir travel - would be extremely valuable work/life balance discussions to have early in this sometimes crazy career.

In full disclosure this has rarely been a problem for me. I've managed to get to where I am today (such as it is) with what I think is a healthy balance of work-to-life. Obviously some, including my spouse, might disagree but the important thing is that I think this is the case. We're talking personal, subjective "balance" here and nobody can define it for you. If you have reached it, you are going to be relatively happier and if you feel imbalanced you are going to feel sad* about it.

Yes, I for damn sure wish for more hours in the day. Yes. Of course. And at each and every major stage there were things being neglected so that I could pursue some other thing. Either in the proximal, days to weeks, or in the long-haul, years to decades(!), perspective. But I have never been an obsessive and any fair read would fail to find any major imbalance.

How did I do it?

I think the most useful and general approach is that you have to be willing to fail.

Let me say it again: YOU HAVE TO BE WILLING TO FAIL!!!!!

I was not, I think, willing to fail at getting the PhD. This was a defined, obtainable target for which the steps were mostly clear to me. Do the research, write that shit up into a dissertation and bob's your uncle.

After that? Well, yes, of course I wanted to succeed career-wise. In one of the professorial paths preferably. But I was willing to...not. To fail.

There have been several defined choice points at which I did the considerably sub-optimal career move for the sake of issues that we shall encompass under "life". (Also career moves which might have in the long run been suboptimal but looked great** at the time. Some of this initial appearance was influenced by "life".) Sometimes I did this out of unthinking ignorance, I will admit. I didn't perhaps realize the magnitude of the risk I was running. But I for damn sure knew there was risk. Risk of not making it in some way. Of not getting on the independent research track. Of not getting funding...or not keeping it. Of letting the lab and research program crash down to nonviability.

This hasn't stopped and it continues to this day.

Is my virtue untested? Some might observe that. From the perspective of some it looks like I have a pretty schweet gig***. From above the waterline it looks okay. Something a disgruntled postdoc or Year 3 faculty member might think is pretty much IT. As in "career accomplished"...all it takes now is running it out like you always wanted to. No risk.

I don't see it that way. I still risk failures of various sorts. Mostly the big axe is the grant funding....and it is a big one, hanging over my head more often than it is not.

So much like the disgruntled postdoc and the terrified junior faculty member...I could always work harder. More. Put in more grants. Squeeze out more papers. Refine my lab efficiency to maximize the data. Chase small project funds. Woo more trainees. Hit the seminar circuit harder. Go to more meetings.

All of this would probably benefit my career. It would make things go better professionally. We'd be more productive, no doubt.

I choose not to. That's it. There's no secret. There's no special case of insulation from the risks of choosing not to work harder than the next person. You risk paying a price.

Balance implies tradeoffs. I've certainly found it to be so. There are costs to go with every benefit. Costs that may be "just" stress, may be health issues (mental or otherwise), may be definable career failures. Having "life" balance makes this inevitable. There will be tradeoffs****, people.

This is my answer to NatC's question. Choose. Choose to take the time. Make room for what is important to you. Realize that by doing so you might fail. You might.

But you know what? These St Kern and Poo types?

I know for damn sure they've failed at life.

And that I was never willing to risk.

__
*don't get a puppy to cheer yourself up.
**so we won't count these, at the time they seemed really pro-career.
***and I do, I do.
****of course it goes both ways. you may be choosing a career path that really isn't compatible with your desire to tour Europe with an opera group every summer. You may have to give up some of the "life" stuff

Share

23 responses so far

Methylone, or beta-keto-MDMA, also causes fatality

(by drugmonkey) May 15 2012

If you've been following along my posts on the substituted cathinones you will recall that cathinone is beta-keto-amphetamine. And much like amphetamine, chemists can hang little bits off the core structure to create new and interesting drugs which may offer different subjective experiences. For people who are into that sort of thing. The compound termed "Methylone" is the cathinone cousin of 3,4-methylenedioxymethamphetamine or MDMA. Which we've discussed a time or two on this blog. As we've also discussed, MDMA can result in significant medical emergency and death. Yes, really, it is the MDMA.

ResearchBlogging.orgA Case Report has just popped up on the preprint queue of the Journal of Analytical Toxicology. In it, Pearson and colleagues detail three cases of fatality involving the methylone compound. For me the interest is the way this slots neatly into the Case Reports on MDMA fatalities, especially given the drug-discrimination paper that was our first introduction to the cathinones on this blog. Although there is great diversity, MDMA cases frequently involve an individual who was "found collapsed" by friends. Emergency medical services are invoked, whereupon the individuals are frequently found with high body temperature, rhabdomyolysis, hyponatremia (dilute blood) and may have seizure-like symptoms. Cardiac arrest is not uncommon during the course of care, as is cascading organ failure. Diversity rules the day. Some individuals have been rave dancing, some have not. Some were exposed to a broad array of other psychoactives. Alcohol, nicotine and cannabis are very common but you also see methamphetamine, caffeine and a list of other stimulant/entactogen/hallucinogen class drugs. The denialists like to point to the other factors as causal, insisting that "pure MDMA" is as safe as sea salt. My position is that the great similarity of clinical courses across the diversity of "other factors" makes it even more convincing that the single shared factor, i.e., MDMA, is the causal factor. ....plus there's this little thing called the preclinical literature.

As always with Case Reports, the work by Pearson et al. will be less than satisfying. It is only through the gradual building of the Case Reports and the addition of preclinical investigations that we will really know what is going on. But every journey starts with a single step....

The second case is the most canonical, to my eye. A 19 year old woman at a rave was observed to collapse, briefly recover, claim to "not feel well" and then exhibit seizure-like symptoms. She went into asystole en route to the Emergency Department and had a body temperature of 103.9 F. She was found negative for cocaine metabolite, cannabinoids,
opiates, benzodiazepines, phencyclidine, amphetamines, barbiturates, methadone and propoxyphene on immunoassay and positive for methylone and lamotrigine. Wait, what? This anticonvulsant sodium channel blocker is a most interesting finding. Was it being used intentionally (by the user or the tablet manufacturer) to modulate the methylone effect on monoamines? Perhaps. Or was she an epileptic prescribed an anticonvulsant? That would be interesting given this prior MDMA-related Case and the Giorgi et al. 2005 preclinical study.

Case 1 is a little more unusual, if we're assuming methylone acts much like MDMA. In this case a 23 year old male was acting erratically in public and was detained by the police and transported to the ED. This one sounds a bit more like a classical amphetamine case, with reports of forced restraint, combativeness and, sigh, the strength-of-five*-men thing. Initial symptoms included rhabdomyolysis, a body temperature of 105.9F, seizure and renal failure. After about 3.5 hrs of care a series of cardiac arrest/recovery events culminated in a fatal arrest about 24 hrs after admission. The blood workup detected detected methylone, dextromethorphan, cotinine, caffeine and lidocaine and the Medical Examiner ruled it due to methylone. As we've occasionally seen from the outside of the deaths of the rich and famous, the MEs are seemingly going on an assessment of drug levels to reach their decision. One might assume that the levels of the other drugs were considered to be below the threshold for causing a death. Naturally, we are in the purest speculation territory to start dreaming up drug interaction stories. For me, the strength will eventually lie in matching up the constellation of clinical symptoms with all the cases of fatality and medical emergency that involve methylone. I'd like to know a bit more about the dextromethorphan, however, given that it is degraded by the same CYP2D6 hepatic enzyme which degrades MDMA and, presumably, methylone. Dextromethorphan is also capable of causing serotonin syndrome, thus might have the same direction of effect as methylone in this context, i.e., this may support a relatively simple additive-effects conclusion.

The final case is just plain disturbing. A 23 year old male was acting erratically in an after-hours club when management had him secured to a chair in a van outside with plastic wrap. He was left there for 3-4 hours before being discovered. Paramedics found low blood pressure, weak (but rapid) heart rate and convulsions. Upon arrival at the ED, he had body temperature of 107 F and died after about 45 minutes of attempted life support. He had 0.03 g/dL blood alcohol concentration and methylone, in addition to several therapeutics administered in the ER (but might possibly have obscured recreational use of benzodiazepines and synthetic opiates). A positive immunoassay for cannabinoids was not confirmed on followup analysis.

I think you can see that being wrapped in a chair with plastic wrap for 3-4 hours in a van might have possible had effects. I'm most concerned about the physical exertion that might have been going on, much like in Case 1 in which the guy was struggling against police. The body heat has to come from somewhere and muscular exertion (due to intentional activity) could be that somewhere. Note that in Malignant Hyperthermia, seizure-like muscular contraction can provide that same input to the system. This would be relevant to all three cases.

As I mentioned above, this is the beginning of the story. By no means can three Cases nail down a connection with high confidence. But this is all strikingly familiar and dovetails with the aforementioned drug-discrimination finding and a recent report of neuropharmacological similarity of methylone and MDMA. So I'm betting we'll see more of these Case Reports of medical emergency and death that involve methylone.

And the profiles are going to look just like the ones involving MDMA.
__
*well, at least it was five, not ten.

Julia M. Pearson, Tiffanie L. Hargraves, Laura S. Hair, Charles J. Massucci, C. Clinton Frazee III, Uttam Garg, & B. Robert Pietak (2012). Case Report: Three Fatal Intoxications Due to Methylone Journal of Analytical Toxicology

Share

6 responses so far

Not all work/life balance issues are equal

(by drugmonkey) May 15 2012

There are differences in importance within the scientific career arcs, for different work/life balance issues. And yes, the reason most presentations sponsored by your local post-doc association and/or academic society focus on child-bearing and child-rearing issues is because they are deemed most important.

So while you are feeling miffed at "yet another one focused on the family" try to keep your shit together.

Is it that you are genuinely unable to get the info you need from these or another source? Or is it that you are sitting there fuming about your *perception* that the world finds your issues unimportant or is "telling you" to reproduce? Because some of that is on you and you need to deal.

Can you really not generalize the points being made for your own situation? Elder care, spouse with disability, self with disability... sure, there are differences but there are also a lot of parallels. So take the baby-focused stuff and adjust it for your situation. Interpret!

Or is it that the world does not accept your issue of "balance" as being important?

"I can't go to that meeting, I have my first Ironman that weekend!"

or perhaps,

"My pitbull needs walkies three times a day so I'll be missing for two hours at lunchtime"

yeah, good luck with that.

UPDATE: posts from microdro and BabyAttachMode. The latter reminded me that I failed to link to this trigger for the day's discussion. In it one Clara B. Jones (@cbjones1943) opines:

It is my personal opinion that the major disadvantage for females in
research science careers concerns how to arrange UNDIVIDED, UNINTERRUPTED,
FOCUSED TIME...sometimes, for protracted &/or unpredictable periods.
10. My own "solution" was to surrender custody of my children; however, I
am not recommending this choice to anyone else and know, from personal
experience, that this decision is one that most females are averse to
thinking about.

you know, in case you think *I* make outrageous statements or anything.....

Share

84 responses so far

Sink or swim: In theory I'd be all over it

(by drugmonkey) May 14 2012

@Neuropolarbear opined:

Now that my lab is collecting data, I think my students would be more productive if I leave and stop pestering them for 2 months.

Stop pestering and stop helping them. And maybe I really mean postdocs rather than students. But I often think this.

Trainees would in many cases be better served if the PI said "Hey guys, I'm taking off on sabbatical, see you in six months or so."

I've never had the nerve to try that one out though. I can't see my way to risking my precious projects that way. Either that or I can't bear the thought of having a trainee really bollocks up their training stint with me to the point that it is an abject failure...and think I could have been more involved in oversight.

I worry, however, that this hovering weakens them.

So how about it, PI-tariat? How long would you let your trainees go without having any decent idea what they were up to? More than two weeks? More than a month?

....Six months????

Share

17 responses so far

Why did nobody tell me about this band?

(by drugmonkey) May 11 2012

Share

7 responses so far

This I know: NIH Grants

(by drugmonkey) May 11 2012

Nobody really "knows what they are talking about" when it comes to #NIHGrants.

We all muddle along as best we can and persuade ourselves we have a partial clue.

That part is just to keep from going insane, though.

Share

5 responses so far

Older posts »

Bad Behavior has blocked 923 access attempts in the last 7 days.